In addition, in those patients with BRAF+ tumours, in whom serum was available for analysis, there was no difference in PFS between patients in whom BRAF mutations could be detected in the serum compared with those patients in whom cfDNA BRAF mutations were not detected (n=45, HR 1.08, 80% confidence interval 0.69, 1.68, two-sided p value=0.826, Figure 2). This evidence concerns the gene BRAF and neoplasm.